No Data
How to Capitalize on the Ongoing Bull Market for Chinese Stocks
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.
Continued high investment in R&D and advancing market expansion, Autobio Diagnostics' first-half revenue and net profit both doubled, according to the announcement.
1. Autobio Diagnostics achieved growth in both H1 revenue and net profit, with the proportion of research and development expenses increasing continuously in total revenue. 2. The proportion of the company's reagent business revenue did not increase as expected. 3. The company plans to add actual production support for subdivided fields in the project of expanding the production capacity of in vitro diagnostic products.
Annual Financial Report
FINANCIAL STATEMENTS
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.